TrialLeukemia2023

Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.

Delphine Réa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.